Houston's first clinic for treatment of patients still coping with symptoms of COVID-19 has opened at UT Physicians, the clinical practice of McGovern Medical School at University of Texas Health Science Center at Houston.
The clinic, part of the new UTHealth COVID-19 Center of Excellence, is staffed by specialists in cardiology, general medicine, neurology, infectious disease, pulmonology, psychiatry, and otorhinolaryngology (ear, nose, and throat). Telehealth and in-person visits are available.
"The UTHealth COVID-19 Center of Excellence brings together our university's experts in adult and pediatric specialty care, public health, biomedical research, and big data analytics — all working to provide the best outcomes for our patients, the best public health and prevention practices for our community, and the best therapies for the virus' short- and long-term impacts," Dr. Giuseppe Colasurdo, president of UTHealth, says in an October 15 release.
Among other things, the COVID-19 Center of Excellence will work on developing reliable testing for the coronavirus, authenticating effective therapies, applying analytics and artificial intelligence to care and research, and collecting virus samples for a "biobank" to study how genetics affects the virus' severity.
Since the emergence of the coronavirus pandemic, scientists and physicians at McGovern Medical School have led clinical trials and treatment protocols, including one of the world's first double-lung transplants for a coronavirus patient. UTHealth is participating in some of the largest national clinical trials to help COVID-19 patients heal, such as studies to prevent progression of the disease and studies seeking proven treatments for critically ill patients.
In one of the country's first randomized clinical trials of its kind, an $8 million grant from the National Institutes of Health is financing a UTHealth study of whether infusions of convalescent plasma can prevent the progression of COVID-19. Another research team is evaluating whether an oral HIF (hypoxia-inducible factor) inhibitor can protect the lungs of COVID-19 patients. The inhibitor is designed to trigger the body's protective response to low oxygen levels.
At the same time, researchers at UTHealth's Cizik School of Nursing are studying the socioeconomic and mental health effects of the virus on Hispanics, while members of the MD Anderson UTHealth Graduate School of Biomedical Sciences are exploring how the time of day a medication is taken might help a COVID-19 patient. In addition, experts at UTHealth's School of Biomedical Informatics are using big data to fight COVID-19.
"Within our six schools, we have the broad expertise that has positioned us as one of the few universities to help our community, Texas and the country through the pandemic and beyond," says Michael Blackburn, executive vice president and chief academic officer of UTHealth. "That starts with amazing clinical care, COVID-19 trials, real-time translational research, and expert knowledge from our public health leaders."
The School of Public Health is leading establishment of a study to be conducted with partners throughout Southeast Texas to assess the virus' long-term consequences, determine factors that contribute to severe outcomes, and enable UTHealth experts to develop and use treatments more effectively. In addition, a community information exchange will be built to connect vulnerable populations with healthcare and social service providers.
"In these unprecedented times, the six schools at UTHealth are rapidly evolving the science and medical care for patients with COVID-19 and our community," says Dr. Bela Patel, vice dean of healthcare quality at McGovern Medical School. "Prevention, new therapeutics, and post-COVID-19 care for our patients with prolonged COVID-19 disease is the mission for the UTHealth Center of Excellence for COVID-19."